Gaia Griguolo· @GaiaGriguolo · X·· 2 天前评分70
正文 · 原文
PANKU-Breast01 presented at #ESMO26
Iza-bren vs CT in HR+/HER2- after ET and 1 or 2 lines of CT
✅️ significantly improved PFS
Mostly hematologic toxicity, 1% ILD events
@OncoAlert
214 浏览 · 5 赞 · 5 转发 · 0 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：Gaia Griguolo · x.com